Opendata, web and dolomites


Reg-X310: new disruptive medicine for faster exit from aplasia afetr agressive chemotherapy of hematologic malignancies

Total Cost €


EC-Contrib. €






 ExitAplasia project word cloud

Explore the words cloud of the ExitAplasia project. It provides you a very rough idea of what is the project "ExitAplasia" about.

innovation    2027    immunity    70    sterile    injection    world    founded    recovery    regeneration    points    tremendous       aplasia    exitaplasia    accelerating    triggers    pasteur    marking    deaths    hospital    10    exit    acute    pain    clinical    99    ce    health    substantially    breakthrough    share    acquired    company    famous    cells    reformulate    extremely    relation    decrease    market    21    medicine    risk    deficient    patients    days    infection    regstem    cancer    2023    leukaemia    treatment    game    french    intravenous    global    chemotherapy    networks    solution    explore    turnover    disrupt    red    speeds    blood    least    paris    situation    length    found    day    room    causes    14    with    off    destruction    feasibility    25    improvement    innovative    dying    severe    toxicological    complete    x310    death    stay    actual    reg    shortening    million    jobs    aggressive    awarded    costing    business    portion    stakeholder    patient    healthcare    start    difficult    morbidity    broaden    spin    white    opportunity    validation    commercialisation    faster    fragile    changing    speed   

Project "ExitAplasia" data sheet

The following table provides information about the project.


Organization address
city: PARIS
postcode: 75014
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-11-01   to  2019-04-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    REGSTEM FR (PARIS) coordinator 50˙000.00


 Project objective

With more than 3.7 million new cases and 1.9 million deaths each year, cancer represents the second most important cause of death and morbidity in Europe; a significant portion is treated by chemotherapy, which triggers the destruction of red and white blood cells: aplasia. This aggressive treatment results in a severe deficient immunity and an extremely fragile health, which causes patients with leukaemia, for example, to stay 21 days at the hospital in a sterile room costing in average €25,000 per day. In this extremely difficult situation, RegStem has found the high-potential solution: the new Reg-X310 medicine which allows faster red and white blood cells regeneration, accelerating exit from aplasia and shortening hospital length of stay of at least 4 days. It is a tremendous improvement in relation to only existing medicine that speeds out aplasia for only one day. This breakthrough innovation will speed up recovery, decrease the risk of dying from a hospital-acquired infection (~7% less), and decrease healthcare cost for around €100,000/patient. Reg-X310 is a game-changing innovation which will substantially improve the treatment of aplasia and disrupt the market. Reg-X310 is being developed by RegStem, a French awarded innovative company, founded as a spin-off of the world-famous Pasteur Institute in Paris. The ExitAplasia project will allow the company to reformulate the Reg-X310 into an intravenous injection and to start the toxicological and clinical validation as well as the CE marking, necessary for the commercialisation in Europe. To accomplish this goal, RegStem will complete a feasibility study to further analyse users’ pain points and actual trends, as well as broaden European key stakeholder networks and explore new business opportunity. RegStem will lead the European and global acute leukaemia market with 10% market share in 2023 and up to 70% before 2027, which will result in €14 and €99 million turnover, and more than 20 new European jobs

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EXITAPLASIA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EXITAPLASIA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

QTB4AMR (2019)

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Read More  

HUD (2018)


Read More